AWA do zlecenia 045/2012 - AOTM

Copaxone (octan glatirameru) AOTM-OT-4351-1/2012
I linia leczenia chorych na stwardnienie rozsiane w postaci rzutowo-remisyjnej
13. Źródła
Piśmiennictwo
1. AAFP 2004
2. AAN 2002
3. ABN 2009
4. AFSSAPS 2004
5. AGDHA 2010
6. AWMF 2008
7. Balak 2012
8.
9. Banwell, 2011
10. Bell 2007
11. Cadavid 2007
12. Cadavid 2009
13. Cadavid 2011
14. CADTH 2010
15. Calabrese 2012
16.
17.
Carra 2008
American Academy of Family, Phisicians Diagnosis and Management of Multiple
Sclerosis http://www.aafp.org/afp/2004/1115/p1935 html
American Academy of Neurology, Disease modifying therapies in multiple sclerosis:
Subcommittee of the American Academy of Neurology and the MS Council for Clinical
Practice Guidelines
http://guidelines.gov/content.aspx?id=4099
Revised (2009) Association of British Neurologists’guidelines for prescribing in multiple
sclerosis
http://www.theabn.org/abn/userfiles/file/ABN MS Guidelines 2009 Final%281%29.pdf
Agence Francaise de Securite Sanitaire des Produits de Sante, Rapport public d’evaluation
(AOUT 2004)
http://ansm.sante fr/var/ansm_site/storage/original/application/7485425fa8e954a99a54a8c
9024b51b5.pdf
Australian Government Department of Health and Ageing, Schedule of pharmaceutical
benefits
http://www healthpolicy.cn/rdfx/jbywzd/gjjy2/adly/ywml/201002/P020100227576500941
349.pdf
Product information Copaxone pre-filled syringe
http://pbs.gov.au/meds%2Fpi%2Fswpcopax10210.pdf
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellsschaften,
Diagnostik und Therapie der Multiplen Sklerose
http://www.awmf.org/uploads/tx szleitlinien/030-
050 S1 Multiple Sklerose Diagnostik und Therapie 10-2008 10-2013.pdf
Balak D.M.W., Hengstman, G.J.D. et al Cutaneous adverse events associated with
disease-modifying treatment in multiple sclerosis: a systematic review Multiple Sclerosis
Journal 0(0) 1–13 2012
Banwell B., Bar-Or A., Giovannoni G. et al Therapies for multiple sclerosis:
considerations in the pediatric patient. Nat. Rev. Neurol. 7, 109–122 (2011)
http://www.sickkids.ca/brainnetwork/Portals/0/speakers/Banwell-nrneurol.pdf
Bell C, Graham J, Earnshaw S, Oleen-Burkey M, et al, Manag Cost-effectiveness of four
immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model
based on long-term clinical data, Care Pharm 2007, 13(3):245-61.
Cadavid D, Wolansky L, Cook S et al. Betaseron versus copaxone in multiple sclerosis
with triple-dose gadolinium and 3 Tesla MRI Endpoints (BECOME): announcement of
secondary clinical outcome. Friday, 12 October 2007 Immunomodulation
Cadavid D, Wolansky LJ, Skurnick J et al. Efficacy of treatment of MS with IFNbeta-1b
or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009 Jun
9;72(23):1976-83.
Cadavid D, Kim S., Peng B., et al Clinical consequences of MRI activity in treated
multiple sclerosis. Multiple sclerosis Journal 2011; 17(9):1113-1121.
Canadian Agency for Drugs and Technologies in Health, Investigating Chronic
Cerebrospinal Venous Insufficiency for the Treatment of Multiple Sclerosis
http://www.cadth.ca/media/pdf/Chronic Cerebrospinal Venous Insufficiency MS es-
15 e.pdf
Calabrese M, Bernardi V, Atzori M, et al Effect of disease-modifying drugs on cortical
lesions and atrophy in relapsing–remitting multiple sclerosis. Mult Scler. 2012
Apr;18(4):418-24.
http://msj.sagepub.com/content/18/4/418
Carra A, Onaha P, Sinay V et al. A retrospective, observational study comparing the four
available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J
Neurol. 2003 Nov;10(6):671-6.
Analiza weryfikacyjna Agencji Oceny Technologii Medycznych 108/113